Composition employing a novel human kinase

Details Composition employing a novel human kinase Composition employing a novel human kinase

2007-11-20

2007-11-20

Prouty, Rebecca E. (Department: 1652)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Transferase other than ribonuclease

C536S023200

Reexamination Certificate

active

10702496

ABSTRACT:
This invention provides compositions, organisms and methodologies employing a novel human protein kinase, MCRK1. The novel human kinase has sequence homology to rat myotonic dystrophy kinase-related Cdc42 binding kinase (MRCK) alpha. The gene encoding the novel kinase is localized in locus 11q13 of human chromosome 11. The novel protein kinase comprises multiple functional/structural domains that include a kinase domain, a pkinase_C domain, a DAG-PE binding domain, and a CNH domain. The sequence and structure similarity between the novel human protein and rat MRCK alpha indicates that the novel human protein may function as a downstream effector of Cdc42 in cytoskeleton reorganization.

REFERENCES:
patent: 4489710 (1984-12-01), Spitler
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4569789 (1986-02-01), Blattler et al.
patent: 4625014 (1986-11-01), Senter et al.
patent: 4638045 (1987-01-01), Kohn et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4751180 (1988-06-01), Cousens et al.
patent: 4935233 (1990-06-01), Bell et al.
patent: 5459039 (1995-10-01), Modrich et al.
patent: 5498531 (1996-03-01), Jarrell
patent: 5919619 (1999-07-01), Tullis
patent: 6506559 (2003-01-01), Fire et al.
patent: 2004/0038881 (2004-02-01), Bandman et al.
patent: WO 89/10134 (1989-11-01), None
patent: WO 97/07668 (1997-03-01), None
patent: WO 97/07669 (1997-03-01), None
patent: WO 99/14346 (1999-03-01), None
patent: WO 99/27132 (1999-06-01), None
patent: WO 00/44895 (2000-08-01), None
patent: WO 00/63364 (2000-10-01), None
patent: WO 00/73469 (2000-12-01), None
patent: WO 01/29058 (2001-04-01), None
patent: WO 01/36646 (2001-05-01), None
patent: WO 01/66594 (2001-09-01), None
patent: WO 01/68836 (2001-09-01), None
patent: WO 01/70949 (2001-09-01), None
patent: WO 01/75067 (2001-10-01), None
patent: WO 01/75164 (2001-10-01), None
patent: WO 01/92513 (2001-12-01), None
patent: WO 02/08399 (2002-01-01), None
patent: WO 02/18557 (2002-03-01), None
patent: WO 02/24924 (2002-03-01), None
patent: WO 02/24924 (2002-03-01), None
patent: WO 02/46384 (2002-06-01), None
patent: 02/81517/ (2002-10-01), None
patent: WO 02/081731 (2002-10-01), None
patent: WO 03/050084 (2003-06-01), None
PIR Accession No. AAC02941. (Feb. 1998).
Hayashi, K. et al., “Activity and substrate specificity of the murine STK2 Serine/Threonine kinase that is structurally related to the mitotic regulator protein NIMA ofAspergillus nidulans,”Biochem. Biophys. Res. Commun., 264(2):449-56 (1999).
Aravind, L. and Koonin, E.V., “Phosphoesterase domains associated with DNA polymerases of diverse origins,”Nucleic Acids Res., 26(16):3746-52 (1998).
Meyers, R.M. et al., “Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA:DNA duplexes,”Science, vol. 230 (4731):1242-1246 (1985).
Database GenEmbl, on STN, AN AF021935, Leung, T. et al., “Myotonic Dystrophy Kinase-Related Cdc42-Binding Kinase Acts as a Cdc42 Effector in Promoting Cytoskeletal Reorganization,” Sequence Comparison, pp. 18-21.
Collins, F.S., “Generation and initial analysis of more that 15,000 full-length human and mouse cDNA sequences,”Proc. Natl. Acad. Sci.USA, 99(26):16899-16903 (2002).
Database GenCore on STN, AN AAD34229, Bandman, O. et al., Database N—Geneseq—Jan. 29, 2004 (WO 02/18557-A2), Mar. 7, 2002, Sequence Comparision, pp. 1-4.
Altschul et al.; “Gapped Blast and PSI-Blast: A New Generation of Protein Database Search Programs”, Nucleic Acids Research, 1997, pp. 3389-3402, vol. 25, No. 17, Oxford University Press.
Berger P. et al.; “Loss of Phosphatase Activity in Myotubularin-Related Protein 2 is Associated With Charcot-Marie Tooth Disease Type 4B1”, Human Molecular Genetics, 2002, pp. 1569-1579, vol. 11, No. 13, Oxford University Press.
Boe R. et al.; “The Protein Phosphatase Inhibitor Okadaic Acid Induces Morphological Changes Typical of Apoptosis in Mammalian Cells”, Experimental Cell Research 195, 1991, pp. 237-246, Academic Press, Inc.
Bottini N. et al.; “Low-Molecular-Weight Protein Tyrosine Phosphatase and Human Disease: In Search of Biochemical Mechanisms”, Archivum Immunologiae et Therapiae Experimentalis, 2002 pp. 95-104, vol. 50.
Brown-Shimer, et al.; “Effect of Protein Tyrosine Phosphatase 1b Expression on Transformation by the Human neu Oncogene”, Cancer Research, 52, 1992, pp. 478-448.
Chen et al.; “The Myotonic Dystrophy Kinase-Related Cdc42-Binding Kinase is Involved in the Regulation of Neurite Outgrowth in PC12 Cells”, The Journal of Biological Chemistry 1999, pp. 19901-19905, vol. 274, No. 28, The American Society for Biochemistry and Molecular Biology, Inc.
Delagrave et al.; “Recursive Ensemble Mutagenesis”, Protein Engineering, 1993, pp. 327-331, vol. 6 No. 3, Oxford University Press.
Dong et al.; “Cdc42 Antagonizes Inductive Action of cAMP on Cell Shape, Via Effects of the Myotonic Dystropht Kinase-Related Cdc42-Binding Kinase(MRCK)on Myosin Light Chain Phosphorylation”, European Journal of Cell Biology Apr. 2002, pp. 231-242, vol. 81.
Engelman et al.; “Identifying Nonpolar Transbilayer Helices in Amino Acid Sequences of Membrane Proteins”, Ann. Rev. Biophys. Chem. 1986, pp. 321-353, vol. 15, Annual Reviews Inc.
Florea et al.; “A Computer Program for Aligning a cDNA Sequence With a Genomic DNA Sequence”, Genome Research 1998, pp. 967-974, vol. 8, Cold Spring Harbor Laboratory Press.
Gossen et al.; “Transcriptional Activation by Tetracyclines in Mammalian Cells”, Science Jun. 23, 1995, pp. 1766-1769, vol. 268.
Guatelli et al.; “Isothermal, In Vitro Amplification of Nucleic Acids by a Multienzyme Reaction Modeled After Retroviral Replication”, Proc. Natl. Acad. Sci. USA, Mar. 1990, pp. 1874-1878, vol. 87.
Haseloff et al.; “Simple RNA Enzymes With New and Highly Specific Endoribonuclease Activities”, Nature, Aug. 18, 1988, pp. 585-591, vol. 334.
Hyrup et al.; “Peptide Nucleic Acids(PNA):Synthesis, Properties and Potential Applications”, Bioorganic & Medicinal Chemistry, 1996, pp. 5-23, vol. 4, No. 1, Elsevier Science Ltd., Great Britain.
Ishida et al.; “Treatment of Myeloid Leukemic Cells With the Phosphatase Inhibitor Okadaic Acid Induces Cell Cycle Arrest at Either G1/S or G2/M Depending on Dose”, Journal of Cellular Physiology, 1992, pp. 484-492.
Janssens et al.; “Protein Phosphatase 2A: A Highly Regulated Familyof Serince/Threonine Phosphatases Implicated in Cell Growth and Signaliing,”Biochem, J., 353, 2001, pp. 417-443.
Kedra et al.; “The Germinal Center Kinase Gene and a Novel CDC25-Like Gene are Located in the Vicinity of the PYGM Gene on 11q13”, Hum. Genet., 1997, pp. 611-619, vol. 100.
Keen et al.;Rapid Detection of Single Base Mismatches as Heteroduplexes on Hydroling Gels, Trends in Genetics, 1997, p. 5, vol. 7.
Kwoh et al.; “Transcription-Based Amplification System and Detection of Amplified Human Immunodefieiency Virus Type 1 With a Bead-Based Sandwich Hybridization Format”, Proc. Natl. Acad. Sci. USA, Feb. 1989, pp. 1173-1177, VOI.. 86.
Lam et al.; “Characterization of a Monoclonal Antibody Panel Shows That the Myotonic Dystrophy Protein Kinase, DMPK, is Expressed Almost Exclusively in Muscle and Heart”, Human Molecular Genetics, 2000, pp. 2167-2173, vol. 9, No. 4, Oxford University Press.
Lee et al.; “Expression of Small Interfering RNAs Targeted Against HIV-1 rev Transcripts in Human Cells”, Nature Biotechnology, May 2002, pp. 500505, vol. 19.
Leung et al.; “Myotonic Dystrophy Kinase-Related Cdc42-Binding Kinase Acts As a Cdc42 Effector in Promoting Cytoskeletal Reorganization”, Molecular and Cellular Biology, Jan. 1998, pp. 130-140, vol. 18, No. 1 American Society for Microbiology.
Lizardi et al.; “Exponential Amplification of Recombinant-RNA Hybridizaion Probes”, Biotechnology, Oct. 1988, pp. 1197-1202,

Affiliated with

Also associated with

Rating

Composition employing a novel human kinase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Composition employing a novel human kinase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition employing a novel human kinase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3853644